The costs that we referred to in our October 2013 report are the aggregate expenditures on public drug plans. They are expected to increase. That's the cost of the drugs that would be covered under a national pharmacare program.
Parliamentary Budget Officer, Office of the Parliamentary Budget Officer
The costs that we referred to in our October 2013 report are the aggregate expenditures on public drug plans. They are expected to increase. That's the cost of the drugs that would be covered under a national pharmacare program.
See context to find out what was said next.